Search Results

Your search for Guido Marcucci, MD, and Clara D. Bloomfield, MD ,Guido Marcucci, MD, and Clara D. Bloomfield, MD matches 2 pages

Showing 1 - 2

By Guido Marcucci, MD, and Clara D. Bloomfield, MD / July 10, 2013

Molecular Landscaping of Acute Myeloid Leukemia: Are We Relearning the Past or Informing the Future?

Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous disease.1 This concept has been supported by more than 4 decades of studies showing distinct outcomes of subsets of patients that differ in age, disease type (primary vs secondary vs therapy-related), and cytogenetic and...

issues in oncology

leukemia

By The ASCO Post Staff / Wednesday, May 15, 2013 5:39 PM

Study Identifies Possible New Treatment Target for Acute Leukemia

A study has identified microRNA-155 as a new independent prognostic marker and treatment target in patients with cytogenetically normal acute myeloid leukemia (AML). The study was led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital...

Dec

Today In Oncology

Search Results

Your search for Guido Marcucci, MD, and Clara D. Bloomfield, MD ,Guido Marcucci, MD, and Clara D. Bloomfield, MD matches 2 pages

Molecular Landscaping of Acute Myeloid Leukemia: Are We Relearning the Past or Informing the Future?

Study Identifies Possible New Treatment Target for Acute Leukemia

Study Finds Daratumumab Monotherapy Prevented or Delayed Progression From Smoldering to Active Multiple Myeloma

Study Finds Genetic Changes, Elevated Leukemia Risk in Ground Zero First Responders

MRI First Strategy May Be Safe for Prostate Cancer Detection

Addition of SBRT to Systemic Therapy May Improve Outcomes in Select Patients With Locally Advanced Hepatocellular Carcinoma

Epcoritamab Monotherapy for Pretreated Relapsed or Refractory CLL